Paediatric Endocrine Unit, Tygerberg Children's Hospital, University of Stellenbosch, Cape Town, South Africa.
Pediatr Allergy Immunol. 2011 Sep;22(6):614-20. doi: 10.1111/j.1399-3038.2011.01161.x. Epub 2011 Jul 28.
Hypothalamic-pituitary-adrenal axis suppression (HPAS) in asthmatic children treated with inhaled corticosteroids (ICS), with or without nasal steroids (NS), may be more common than previously thought. Only dynamic testing will identify children at risk of adrenal crisis. It is impractical to test all asthmatic children for HPAS with a gold standard adrenal function test, i.e. the metyrapone or insulin tolerance test.
To determine which clinical or biochemical parameter is the most useful screening test for HPAS in asthmatic children.
Twenty-six asthmatic children, 5-18 yr old, on ICS ± NS, not treated with oral or topical steroids in the preceding year were recruited. Height, weight, height velocity, weight velocity and a change in systolic blood pressure from the recumbent to the standing position (ΔSBP) were recorded. Early-morning urine for urinary free cortisol (UFC) and urinary cortisol metabolites (UCM) was collected. UFC was analysed by both a chemiluminescent assay and gas chromatography/mass spectrometry (GC-MS). Morning serum cortisol and adrenocorticotropic hormone (ACTH) levels were measured. The overnight metyrapone test was performed if the fasting morning serum cortisol was >83 nmol/l. HPAS was diagnosed if the ACTH failed to rise >100 pg/ml after metyrapone. Spearman correlation coefficients (r) were calculated between the post-metyrapone ACTH and each variable. A receiver-operating characteristics (ROC) curve was drawn for the most promising test, and the diagnostic performance was calculated.
All clinical and biochemical parameters investigated were weakly and non-significantly correlated with the post-metyrapone ACTH, except for the morning serum ACTH (r = 0.68; p <0.001). The best discrimination between those who have and those who do not have HPAS is a morning serum ACTH level of 11.7 pg/ml. This corresponds to a sensitivity of 0.89 (0.57-0.98), a specificity of 0.77 (0.53-0.90), a positive predictive value of 0.67 (0.39-0.87), a negative predictive value of 0.93 (0.69-0.99), an accuracy of 0.81 (0.61-0.94), a positive likelihood ratio of 3.78 (1.68-9.49) and a negative likelihood ratio of 0.15 (0.03-0.60).
The morning serum ACTH level was found to be the most useful screening test to detect HPAS in this sample of children receiving ICS ± NS. A larger study should be undertaken to refine the diagnostic precision of the morning serum ACTH level.
接受吸入性皮质类固醇(ICS)治疗的哮喘儿童,无论是否同时接受鼻用皮质类固醇(NS)治疗,其下丘脑-垂体-肾上腺轴抑制(HPAS)可能比以前认为的更为常见。只有动态检测才能发现有肾上腺危象风险的儿童。使用金标准肾上腺功能检测(即美替拉酮或胰岛素耐量试验)对所有哮喘儿童进行 HPAS 检测是不切实际的。
确定哪种临床或生化参数是哮喘儿童中 HPAS 最有用的筛查试验。
招募了 26 名年龄在 5-18 岁之间的哮喘儿童,他们正在接受 ICS ± NS 治疗,且在前一年未接受口服或局部皮质类固醇治疗。记录身高、体重、身高增长速度、体重增长速度和从卧位到站立位时收缩压的变化(ΔSBP)。采集清晨尿液用于检测尿游离皮质醇(UFC)和尿皮质醇代谢物(UCM)。使用化学发光分析和气相色谱/质谱(GC-MS)分析 UFC。测量清晨血清皮质醇和促肾上腺皮质激素(ACTH)水平。如果空腹清晨血清皮质醇水平>83 nmol/L,则进行过夜美替拉酮试验。如果美替拉酮后 ACTH 未能升高>100 pg/ml,则诊断为 HPAS。计算了 ACTH 与每种变量之间的 Spearman 相关系数(r)。为最有前途的检测绘制了受试者工作特征(ROC)曲线,并计算了诊断性能。
除了清晨血清 ACTH 外(r=0.68;p<0.001),所有研究的临床和生化参数与 ACTH 之间的相关性均较弱且无统计学意义。最佳区分是否存在 HPAS 的是清晨血清 ACTH 水平为 11.7 pg/ml。这对应于 0.89 的灵敏度(0.57-0.98)、0.77 的特异性(0.53-0.90)、0.67 的阳性预测值(0.39-0.87)、0.93 的阴性预测值(0.69-0.99)、0.81 的准确性(0.61-0.94)、3.78 的阳性似然比(1.68-9.49)和 0.15 的阴性似然比(0.03-0.60)。
在接受 ICS ± NS 治疗的儿童样本中,清晨血清 ACTH 水平被发现是检测 HPAS 最有用的筛查试验。应进行更大规模的研究来提高清晨血清 ACTH 水平的诊断精度。